Notably, in vitro studies propose that activation of the PIK3CA/mTOR pathway may be important in tumours with deficient homologous recombination [18], suggesting a possible role in gaining resistance to poly ADP ribose polymerase (PARP) inhibitors in BRCA1/2 deficient tumours. This evidence concerns the gene PIK3CA and neoplasm.